PLXND1

Across TCGA pan-cancer cohorts, PLXND1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLXND1 data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLXND1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLXND1 expression acts as an unfavorable survival marker.

PDAC, HNSC, and GBM are the cancer types where PLXND1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.288	0.513	.003	19	view →
HNSC	DFS	Median	II,III,IV	0.899	0.991	.005	14	view →
GBM	OS	Quartile	All	0.304	0.658	.001	8	view →
COAD	DFS	Tertile	All	0.911	1.000	.042	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLXND1–PDAC (DFS)

Open the PDAC breakdown →